|Mr. Darrin R. Uecker||Pres, CEO & Director||416.82k||N/A||1966|
|Mr. Brian B. Dow||CFO, Sr. VP of Fin. & Admin., Treasurer and Sec.||309.25k||N/A||1969|
|Dr. Richard Nuccitelli Ph.D.||Chief Science Officer||N/A||N/A||N/A|
|Dr. Holly Hartman Ph.D., J.D.||VP of Bus. Devel. & Corp. Strategy||N/A||N/A||N/A|
|Mr. Edward A. Ebbers||Exec. VP & GM of Dermatology||N/A||N/A||1960|
Pulse Biosciences, Inc. operates as a clinical stage medical therapy company. It engages in the research and development, and commercialization of CellFX system that provides a precise and non-thermal cellular treatment technology delivering nanosecond duration energy pulses that impact cells in treated tissue while sparing surrounding non-cellular tissue primarily for dermatology applications. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was founded in 2014 and is headquartered in Hayward, California.
Pulse Biosciences, Inc.’s ISS Governance QualityScore as of April 1, 2019 is 9. The pillar scores are Audit: 5; Board: 8; Shareholder Rights: 5; Compensation: 10.